Next 10 |
FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwrigh...
Merger completed with Rexahn Pharmace u ticals c reat ing a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates Trading under "OCUP" on the Nasdaq Capital Market to begin No...
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 202...
Gainers: Endurance International (EIGI) +61%.Superior Industries International (SUP) +35%.DBV Technologies (DBVT) +32%.Renren (RENN) +22%.Digital Ally (DGLY) +21%.Dunxin Financial (DXF) +19%.Par Pacific Holdings (PARR) +18%.Tricida (TCDA) +18%.Lumber Liquidators (LL) +17%.Vislink Technol...
Gainers: DBV Technologies (DBVT) +61%, AnPac Bio-Medical Science (ANPC) +16%, Community Health Systems (CYH) +15%, ProPhase Labs (PRPH) +12%, ZIOPHARM Oncology (ZIOP) +10%.Losers: Liquidia Technologies (LQDA) -28%, Jounce Therapeutics (JNCE) -...
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s stockholders approved all of the proposals presented, including: (i) th...
NEW YORK, NY / ACCESSWIRE / July 8, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed t...
NEW YORK , June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphire Pharma, Inc. is fair to Rexahn shareholders. On behalf of Rexahn shareholders, Halper Sad...
Nova LifeStyle (NASDAQ: NVFY ) +105% . More news on: Nova LifeStyle, Inc., TDH Holdings, Inc., Rexahn Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Rexahn Pharmaceuticals (NASDAQ: REXN ) has agreed to merge with privately held Ocuphire Pharma, a developer therapies for eye disorders, in an all-stock deal. More news on: Rexahn Pharmaceuticals, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on the move, Read m...
News, Short Squeeze, Breakout and More Instantly...
Rexahn Pharmaceuticals Company Name:
REXN Stock Symbol:
NYSE Market:
FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwrigh...
Merger completed with Rexahn Pharmace u ticals c reat ing a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates Trading under "OCUP" on the Nasdaq Capital Market to begin No...
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 202...